South Korea
· Delayed Price · Currency is KRW GeneBioTech Co. ,Ltd Statistics
Total Valuation
GeneBioTech Co. ,Ltd has a market cap or net worth of KRW 28.16 billion. The enterprise value is 19.60 billion.
| Market Cap | 28.16B |
| Enterprise Value | 19.60B |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneBioTech Co. ,Ltd has 8.61 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 8.61M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 28.78% |
| Owned by Institutions (%) | n/a |
| Float | 6.09M |
Valuation Ratios
The trailing PE ratio is 11.05.
| PE Ratio | 11.05 |
| Forward PE | n/a |
| PS Ratio | 0.35 |
| PB Ratio | 0.56 |
| P/TBV Ratio | 0.57 |
| P/FCF Ratio | 16.85 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.20, with an EV/FCF ratio of 11.73.
| EV / Earnings | 7.68 |
| EV / Sales | 0.24 |
| EV / EBITDA | 4.20 |
| EV / EBIT | 5.94 |
| EV / FCF | 11.73 |
Financial Position
The company has a current ratio of 2.96, with a Debt / Equity ratio of 0.31.
| Current Ratio | 2.96 |
| Quick Ratio | 1.97 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 3.38 |
| Debt / FCF | 9.43 |
| Interest Coverage | 5.20 |
Financial Efficiency
Return on equity (ROE) is 5.19% and return on invested capital (ROIC) is 3.21%.
| Return on Equity (ROE) | 5.19% |
| Return on Assets (ROA) | 2.96% |
| Return on Capital (ROIC) | 3.21% |
| Revenue Per Employee | 2.12B |
| Profits Per Employee | 67.13M |
| Employee Count | 38 |
| Asset Turnover | 1.16 |
| Inventory Turnover | 4.08 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.04% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -24.04% |
| 50-Day Moving Average | 3,403.70 |
| 200-Day Moving Average | 3,765.95 |
| Relative Strength Index (RSI) | 44.26 |
| Average Volume (20 Days) | 86,939 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GeneBioTech Co. ,Ltd had revenue of KRW 80.50 billion and earned 2.55 billion in profits. Earnings per share was 296.00.
| Revenue | 80.50B |
| Gross Profit | 12.78B |
| Operating Income | 3.30B |
| Pretax Income | 3.01B |
| Net Income | 2.55B |
| EBITDA | 4.66B |
| EBIT | 3.30B |
| Earnings Per Share (EPS) | 296.00 |
Balance Sheet
The company has 24.31 billion in cash and 15.76 billion in debt, giving a net cash position of 8.55 billion or 993.34 per share.
| Cash & Cash Equivalents | 24.31B |
| Total Debt | 15.76B |
| Net Cash | 8.55B |
| Net Cash Per Share | 993.34 |
| Equity (Book Value) | 50.45B |
| Book Value Per Share | 5,859.62 |
| Working Capital | 36.78B |
Cash Flow
In the last 12 months, operating cash flow was 2.15 billion and capital expenditures -477.58 million, giving a free cash flow of 1.67 billion.
| Operating Cash Flow | 2.15B |
| Capital Expenditures | -477.58M |
| Free Cash Flow | 1.67B |
| FCF Per Share | 194.08 |
Margins
Gross margin is 15.88%, with operating and profit margins of 4.10% and 3.17%.
| Gross Margin | 15.88% |
| Operating Margin | 4.10% |
| Pretax Margin | 3.75% |
| Profit Margin | 3.17% |
| EBITDA Margin | 5.79% |
| EBIT Margin | 4.10% |
| FCF Margin | 2.08% |
Dividends & Yields
GeneBioTech Co. ,Ltd does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 9.05% |
| FCF Yield | 5.94% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GeneBioTech Co. ,Ltd has an Altman Z-Score of 3.49.
| Altman Z-Score | 3.49 |
| Piotroski F-Score | n/a |